Analysts forecast that NewLink Genetics Corp (NASDAQ:NLNK) will post earnings per share (EPS) of ($0.30) for the current quarter, Zacks reports. Zero analysts have made estimates for NewLink Genetics’ earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.29). NewLink Genetics posted earnings per share of ($0.49) during the same quarter last year, which would indicate a positive year over year growth rate of 38.8%. The company is scheduled to announce its next quarterly earnings report on Thursday, May 2nd.
On average, analysts expect that NewLink Genetics will report full-year earnings of ($0.90) per share for the current financial year, with EPS estimates ranging from ($1.47) to ($0.12). For the next financial year, analysts forecast that the business will report earnings of ($1.18) per share, with EPS estimates ranging from ($1.23) to ($1.14). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow NewLink Genetics.
NLNK has been the subject of a number of research reports. ValuEngine upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Zacks Investment Research cut shares of NewLink Genetics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Bank of America cut shares of NewLink Genetics from a “neutral” rating to an “underperform” rating in a report on Thursday, January 3rd. Finally, Robert W. Baird lowered their price target on shares of NewLink Genetics from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Thursday, February 28th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $4.50.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Paloma Partners Management Co acquired a new position in NewLink Genetics during the 4th quarter worth approximately $30,000. Rhumbline Advisers lifted its position in shares of NewLink Genetics by 41.4% during the 4th quarter. Rhumbline Advisers now owns 40,387 shares of the biotechnology company’s stock worth $61,000 after buying an additional 11,830 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of NewLink Genetics during the 4th quarter worth approximately $83,000. Russell Investments Group Ltd. purchased a new stake in shares of NewLink Genetics during the 3rd quarter worth approximately $219,000. Finally, Marshall Wace LLP purchased a new stake in shares of NewLink Genetics during the 3rd quarter worth approximately $244,000. Institutional investors own 34.36% of the company’s stock.
NewLink Genetics Company Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.
Featured Story: Google Finance Portfolio Workaround
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.